85 phenotypes from 14 alleles in 19 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Bcl2l11em1(IMPC)H/Bcl2l11em1(IMPC)H C57BL/6NTac-Bcl2l11em1(IMPC)H/H	decreased mean corpuscular hemoglobin	J:211773
	decreased total body fat amount	J:211773
	increased circulating potassium level	J:211773
	increased erythrocyte cell number	J:211773
	increased grip strength	J:211773
	increased large unstained cell number	J:211773
	increased leukocyte cell number	J:211773
	increased lymphocyte cell number	J:211773
	increased spleen weight	J:211773
Bcl2l11tm1.1Ast/Bcl2l11+ B6.129S1-Bcl2l11tm1.1Ast	normal immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11tm1.1Ast/Bcl2l11+ involves: 129S1/Sv * C57BL/6	abnormal lymphocyte physiology	J:58641
	glomerulonephritis	J:58641
	increased IgA level	J:58641
	increased IgG level	J:58641
	increased IgM level	J:58641
	increased susceptibility to autoimmune disorder	J:58641
	premature death	J:58641
	renal glomerular immunoglobulin deposits	J:58641
	vascular inflammation	J:58641
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast B6.129-Bcl2l11tm1.1Ast/J	decreased lymphocyte cell number	J:137609
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast B6.129S1-Bcl2l11tm1.1Ast	abnormal B cell morphology	J:133084
	abnormal leukopoiesis	J:73316
	abnormal lymphocyte physiology	J:73316
	abnormal NK cell morphology	J:123409
	abnormal response to infection	J:123409
	abnormal sympathetic neuron morphology	J:124044
	decreased apoptosis	J:123409
	decreased B cell apoptosis	J:73316
	decreased physiological sensitivity to xenobiotic	J:123409
	decreased T cell apoptosis	J:73316, J:133084
	normal immune system phenotype	J:153846
	increased immature B cell number	J:133084
	increased leukocyte cell number	J:153846
	increased mature B cell number	J:133084
	increased NK cell number	J:123409
	increased regulatory T cell number	J:208318
	increased spleen weight	J:153846
	increased transitional stage B cell number	J:133084
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast B6.129S1-Bcl2l11tm1.1Ast/J	decreased T cell apoptosis	J:153652
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast involves: 129S1/Sv	abnormal CD4-positive, alpha-beta T cell number	J:132819
	abnormal CD8-positive, alpha-beta T cell physiology	J:132819
	abnormal involution of the mammary gland	J:235354
	abnormal splenic cell ratio	J:132819
	decreased splenocyte apoptosis	J:266833
	decreased thymocyte apoptosis	J:266833
	normal hematopoietic system phenotype	J:141545
	increased B cell number	J:132819
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast involves: 129S1/Sv * C57BL/6	abnormal B cell proliferation	J:90963
	abnormal kidney morphology	J:132217
	abnormal lymphocyte physiology	J:58641
	abnormal plasma cell morphology	J:58641
	abnormal renal glomerulus basement membrane morphology	J:132217
	abnormal renal glomerulus morphology	J:58641
	abnormal spleen morphology	J:58641
	abnormal splenic cell ratio	J:132217
	decreased B cell apoptosis	J:90963
	decreased double-positive T cell number	J:58641
	dilated renal tubule	J:58641
	embryonic lethality during organogenesis, incomplete penetrance	J:58641
	enlarged spleen	J:58641
	expanded mesangial matrix	J:58641
	glomerular crescent	J:58641
	glomerulonephritis	J:58641
	increased anti-double stranded DNA antibody level	J:132217
	increased anti-histone antibody level	J:132217
	increased anti-nuclear antigen antibody level	J:132217
	increased anti-single stranded DNA antibody level	J:132217
	increased autoantibody level	J:132217
	increased B cell number	J:58641
	increased blood urea nitrogen level	J:58641
	increased CD4-positive, alpha-beta T cell number	J:58641
	increased CD8-positive, alpha-beta T cell number	J:58641
	increased double-negative T cell number	J:58641
	increased follicular B cell number	J:132217
	increased granulocyte number	J:58641
	increased IgA level	J:58641
	increased IgG level	J:58641
	increased IgM level	J:58641
	increased immature B cell number	J:132217
	increased inflammatory response	J:58641
	increased leukocyte cell number	J:58641
	increased marginal zone B cell number	J:132217
	increased monocyte cell number	J:58641
	increased renal glomerulus apoptosis	J:132217
	increased splenocyte number	J:132217
	increased susceptibility to autoimmune disorder	J:58641
	increased T cell number	J:58641
	increased transitional stage B cell number	J:132217
	normal nervous system phenotype	J:127640
	premature death	J:58641
	renal cast	J:58641
	renal glomerular immunoglobulin deposits	J:58641
	spleen hyperplasia	J:58641
	thrombocytopenia	J:58641
	vascular inflammation	J:58641
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui C57BL/6-Bcl2l11tm1.1Boui	normal immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11tm1.1Boui/Bcl2l11tm2.1Boui C57BL/6-Bcl2l11tm1.1Boui/Bcl2l11tm2.1Boui	normal immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11tm1.1Jad/Bcl2l11+ Not Specified	no abnormal phenotype detected	J:73316
Bcl2l11tm1.1Jad/Bcl2l11tm1.1Jad involves: C57BL/6	abnormal mammary gland development	J:104975
	abnormal mammary gland duct morphology	J:104975
Bcl2l11tm1Ast/Bcl2l11tm1Ast B6.129S1-Bcl2l11tm1Ast	abnormal hippocampus morphology	J:111236
	gliosis	J:111236
Bcl2l11tm1Sjk/Bcl2l11tm1Sjk involves: 129X1/SvJ	abnormal B cell physiology	J:100463
	abnormal spleen marginal zone morphology	J:100463
	increased B cell number	J:100463
	increased B-2 B cell number	J:100463
	increased follicular B cell number	J:100463
	increased immunoglobulin level	J:100463
	increased transitional stage B cell number	J:100463
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui C57BL/6-Bcl2l11tm2.1Boui	normal immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11tm2Rjd/Bcl2l11tm2Rjd B6.129S6-Bcl2l11tm2Rjd	increased fibroblast apoptosis	J:137061
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui C57BL/6-Bcl2l11tm3.1Boui	normal immune system phenotype	J:153846
	increased leukocyte cell number	J:153846
	increased spleen weight	J:153846
Bcl2l11tm3Rjd/Bcl2l11tm3Rjd B6.129S6-Bcl2l11tm3Rjd	decreased thymocyte apoptosis	J:137061
	increased B cell number	J:153652
	increased CD4-positive, alpha-beta T cell number	J:153652
	increased CD8-positive, alpha-beta T cell number	J:153652
	increased splenocyte number	J:153652
Bcl2l11tm4Boul/Bcl2l11tm4Boul involves: C57BL/6	normal hematopoietic system phenotype	J:203181
	normal immune system phenotype	J:203181
Bcl2l11tm4Rjd/Bcl2l11tm4Rjd B6.129S6-Bcl2l11tm4Rjd	increased fibroblast apoptosis	J:137061
Bcl2l11tm4Rjd/Bcl2l11tm4Rjd involves: 129S6/SvEvTac * C57BL/6	normal hematopoietic system phenotype	J:203181
	normal immune system phenotype	J:203181
Bcl2l11tm5Boul/Bcl2l11tm5Boul involves: C57BL/6	normal hematopoietic system phenotype	J:203181
	normal immune system phenotype	J:203181
Bcl2l11tm6.1Boui/Bcl2l11tm6.1Boui Foxp3tm4(YFP/icre)Ayr/Foxp3+ involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL	increased regulatory T cell number	J:208318